GK Wealth Management LLC Purchases Shares of 1,554 Johnson & Johnson $JNJ

Key Points

• GK Wealth Management LLC has purchased 1,554 shares of Johnson & Johnson, valued at approximately $258,000, as part of its first-quarter investments.
• Analysts have a consensus rating of Moderate Buy for Johnson & Johnson, with a target price around $176.29, following various upgrades from research firms.
• The company recently declared a quarterly dividend of $1.30 per share, representing an annual yield of 3.0%, which reflects its strong financial performance with a net margin of 25.00% in the recent quarter.

GK Wealth Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,554 shares of the company's stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Ellsworth Advisors LLC grew its stake in Johnson & Johnson by 3.4% during the 1st quarter. Ellsworth Advisors LLC now owns 44,617 shares of the company's stock valued at $7,399,000 after purchasing an additional 1,450 shares in the last quarter. Intrua Financial LLC boosted its stake in shares of Johnson & Johnson by 27.4% during the 1st quarter. Intrua Financial LLC now owns 18,963 shares of the company's stock valued at $3,145,000 after buying an additional 4,082 shares during the last quarter. Jacobi Capital Management LLC grew its position in shares of Johnson & Johnson by 2.3% during the first quarter. Jacobi Capital Management LLC now owns 35,951 shares of the company's stock worth $5,962,000 after buying an additional 794 shares in the last quarter. Advisors Capital Management LLC grew its position in shares of Johnson & Johnson by 10.9% during the first quarter. Advisors Capital Management LLC now owns 442,801 shares of the company's stock worth $73,434,000 after buying an additional 43,664 shares in the last quarter. Finally, MBL Wealth LLC increased its stake in shares of Johnson & Johnson by 28.4% in the first quarter. MBL Wealth LLC now owns 6,050 shares of the company's stock worth $1,003,000 after buying an additional 1,337 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ traded down $0.40 on Friday, hitting $178.10. 7,220,047 shares of the company's stock were exchanged, compared to its average volume of 7,548,205. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a fifty day moving average of $170.81 and a two-hundred day moving average of $161.30. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The firm has a market cap of $428.93 billion, a PE ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Citigroup increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, UBS Group boosted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.